Copyright
©The Author(s) 2025.
World J Hepatol. Aug 27, 2025; 17(8): 107456
Published online Aug 27, 2025. doi: 10.4254/wjh.v17.i8.107456
Published online Aug 27, 2025. doi: 10.4254/wjh.v17.i8.107456
Table 1 Clinical prevalence of rtCYE and rtCYEI mutations in patients infected with different hepatitis B virus genotypes assessed by direct sequencing, n (%)
Mutation(s) | Genotype A (n = 9) | Genotype B (n = 4266) | Genotype C (n = 23718) | Genotype D (n = 243) |
rtS106C | 0 (0.00) | 56 (1.31) | 1947 (8.21) | 1 (0.41) |
rtH126Y | 7 (77.78) | 75 (1.76) | 759 (3.20) | 3 (1.23) |
rtD134E | 0 (0.00) | 9 (0.21) | 605 (2.55) | 0 (0.00) |
rtL269I | 2 (22.22) | 3939 (92.33) | 14584 (61.49) | 231 (95.06) |
rtS106C+H126Y | 0 (0.00) | 0 (0.00) | 114 (0.48) | 0 (0.00) |
rtS106C+H126Y+D134E | 0 (0.00) | 0 (0.00) | 6 (0.03) | 0 (0.00) |
rtS106C+H126Y+D134E+L269I | 0 (0.00) | 0 (0.00) | 6 (0.03) | 0 (0.00) |
Table 2 Mutation patterns and clinical information of the patients with hepatitis B virus rtCYE/rtCYEI mutations
Patient | Date1 | GT | HBV DNA (log10 IU/mL) | ALT (U/L) | HBeAg | NAs exposure (month) | Direct sequencing | Clonal sequencing (positive clone number/total tested clone number) |
P1 | 2009.02 | C | 8.16 | 55 | + | LAM (19) | rtS106C+H126Y+D134E | rtS106C+H126Y+D134E (18/20), rtS106C+H126Y+D134E+L80I+M204I (1/20), rtS106C+H126Y+D134E+L269I (1/20) |
P2 | 2009.05 | C | 8.66 | 53 | + | LdT (18) | rtS106C+H126Y+D134E+M204I | rtS106C+H126Y+D134E+M204I (19/20), rtS106C+H126Y+D134E+L80I+M204I (1/20) |
P3 | 2012.04 | C | 8.10 | 589 | + | LAM (33) | rtS106C+H126Y+D134E+L80I+L180M+M204I | rtS106C+H126Y+D134E+L80I+L180M+M204I (17/20), rtS106C+H126Y+D134E+L269I+L80I+L180M+M204I (3/20), rtS106C+H126Y+L80I+L180M+M204I (1/20) |
P4 | 2013.06 | C | 6.77 | 375 | + | ADV (55) | rtS106C+H126Y+D134E+L269I+A181V | rtS106C+H126Y+D134E+L269I+A181V (17/20), rtH126Y+L269I+A181V (3/20) |
P5 | 2013.08 | C | 1.60 | 20 | + | ADV (17)→ETV (15) | rtS106C+H126Y+D134E+L269I | rtS106C+H126Y+D134E+L269I (20/20) |
P6 | 2013.08 | C | 5.52 | 20 | - | LdT (16) | rtS106C+H126Y+D134E+L269I+M204I | rtS106C+H126Y+D134E+L269I (18/20), rtS106C+H126Y+D134E+L269I+M204I (2/20) |
P7 | 2008.06 | C | 5.21 | 37 | + | LAM (24)→ADV (18) | rtS106C+H126Y+D134E | rtH126Y (6/20), rtS106C+H126Y+D134E (14/20) |
P8 | 2008.08 | C | 6.61 | 109 | + | LdT (16) | rtS106C+H126Y+D134E+L80I+M204I | rtS106C+H126Y+D134E+L80I+M204I (19/20), rtS106C+H126Y+D134E+L269I+L80I+M204I (1/20) |
P9 | 2009.04 | C | 3.77 | 87 | - | ADV (32) | rtS106C+H126Y+D134E+L269I+N236T | rtS106C+H126Y+D134E+L269I (16/20), rtS106C+H126Y+D134E+L269I+N236T (4/20) |
P10 | 2010.08 | C | 6.88 | 165 | - | LAM (28)→ADV (12) | rtS106C+H126Y+D134E | rtS106C+H126Y+D134E (20/20) |
P11 | 2012.09 | C | 4.50 | 35 | - | LAM (38) | rtS106C+H126Y+D134E+L269I+M204I | rtS106C+H126Y+D134E+L269I+M204I (20/20) |
P12 | 2014.06 | C | 4.18 | 75 | - | LAM (36)→ADV (25) | rtS106C+H126Y+D134E+L269I | rtS106C+H126Y+D134E+L269I (16/20), rtS106C+H126Y+D134E (4/20) |
Table 3 Analysis of clinical features between hepatitis B virus rtCYE/rtCYEI mutation-positive and negative patients, n (%)/median (25th-75th percentiles)
rtCYE/rtCYEI (+) (n = 12) | rtCYE/rtCYEI (-) (n = 28224) | Univariate OR (95%CI) | P value | |
Age (years) | 43 (33-49) | 42 (32-51) | 3.78 (-7.88-6.95) | 0.903 |
Gender (male) | 10 (83.33) | 22419 (79.43) | 0.77 (0.17-3.53) | 1.00 |
Genotype (A/B/C/D%) | 0/0/100/0 | 0.03/15.11/84.00/0.86 | 0.515 | |
HBV DNA (log10 IU/mL) | 5.37 (3.40-6.69) | 4.03 (2.72-6.00) | 0.64 (-1.96-0.56) | 0.275 |
ALT (U/L) | 65.0 (35.5-151.0) | 38.00 (23.0-72.0) | 57.48 (-153.95-71.37) | 0.473 |
AST (U/L) | 33.0 (29.0-114.5) | 35.0 (25.0-66.0) | 73.71 (-179.46-109.51) | 0.635 |
TBIL (µmol/L) | 13.85 (12.5-21.1) | 14.2 (10.2-22.0) | 20.32 (-29.46-50.21) | 0.610 |
HBeAg (+) | 7 (58.33) | 17438 (61.78) | 0.87 (0.28-2.73) | 0.806 |
LAM/LdT exposure1 | 9 (75.00) | 15419 (54.63) | 0.40 (0.11-1.48) | 0.260 |
ADV exposure1 | 6 (50.00) | 16971 (60.13) | 1.51 (0.49-4.68) | 0.474 |
ETV exposure1 | 1 (8.33) | 8698 (30.82) | 4.90 (0.63-37.96) | 0.169 |
TDF exposure1 | 0 (0.00) | 390 (1.38) | 0.986 (0.98-0.99) | 1.000 |
TAF exposure1 | 0 | 0 |
Table 4 Drug susceptibility analysis of representative hepatitis B virus strains, mean ± SD
Viral strain | Tenofovir disoproxil fumarate | ||
EC50 (μmol/L)2 | Fold3 | P value1 | |
rtWT (wild-type) | 5.79 ± 1.59 | 1.0 | - |
rtWT (laboratory) | 5.90 ± 1.95 | 1.0 | 0.93 |
rtCYE | 7.41 ± 0.97 | 1.3 | 0.09 |
rtCYEI | 8.51 ± 1.29 | 1.5 | < 0.05 |
rtCYE+M204I | 6.95 ± 0.64 | 1.2 | 0.17 |
rtCYE+L80I+L180M+M204I | 6.92 ± 1.69 | 1.2 | 0.31 |
rtCYEI+M204I | 8.92 ± 0.87 | 1.5 | < 0.05 |
rtCYEI+L80I+L180M+M204I | 10.23 ± 1.01 | 1.8 | < 0.05 |
rtCYEI+A181V | 36.15 ± 5.99 | 6.2 | < 0.05 |
rtCYEI+N236T | 57.33 ± 5.30 | 9.9 | < 0.05 |
- Citation: Si LL, Fan ZP, Liu WH, Chen RJ, Chen XY, Ji D, Li L, Chen C, Liao H, Wang J, Xu DP, Zhao J, Liu Y. Hepatitis B virus rtCYE/rtCYEI mutations may contribute limited tenofovir resistance: Analysis of a large sample of Chinese patients. World J Hepatol 2025; 17(8): 107456
- URL: https://www.wjgnet.com/1948-5182/full/v17/i8/107456.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i8.107456